Extended Flushing Interval for Implanted Port Device Maintenance
Trial Summary
What is the purpose of this trial?
Implanted port devices (IPD) play an essential role in the safe administration of cancer treatments by providing a device to safely administer caustic chemotherapy agents. The current recommended frequency of flushing the IPD per manufacturers guidelines is every 4-6 weeks. The purpose of this study is to find out if extending IPD flushes to every 12 weeks is safe and if it is just as effective as every 4 week flushing.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
How does the extended flushing interval for implanted port device maintenance differ from other treatments?
Research Team
Bret E. Friday
Principal Investigator
Essentia Health
Eligibility Criteria
This trial is for adult hematology/oncology patients with an implanted port device (IPD) used for chemotherapy, who haven't had complications like Deep Vein Thrombosis in the last 4 weeks. Participants should not need to use their IPD outside of routine flushing for the next 12 weeks and must be able to give informed consent and understand English.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either IPD standard maintenance flushes and port assessments every 4 weeks or every 12 weeks for an initial 12-week interval
Continuation
Participants may continue to receive either IPD standard maintenance flushes and port assessments every 4 weeks or every 12 weeks for up to an additional three 12-week cycles
Follow-up
Participants are monitored for long-term rate of IPD patency and other outcomes up to 48 weeks post-randomization
Treatment Details
Interventions
- Reduced IPD Flush Schedule (Procedure)
- Standard IPD Flush Schedule (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Essentia Health
Lead Sponsor
Minnesota Cancer Clinical Trials Network
Collaborator